Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

iLOQ products are available from 1,000 retailers around the world

Finnish digital locking company, iLOQ, is growing rapidly. The Company's access management solutions are now available in 1,000 locations in nearly 30 countries around the world. iLOQ was founded in 2003. In 2007, iLOQ introduced the world's first battery-free digital locking system that harvests energy for unlocking from the motion of pushing the key into the lock. In 2016, iLOQ released the first lock cylinder that generates the electrical power it needs for unlocking from an NFC-compatible smartphone.iLOQ employs more than 170 people. It currently has sales offices in Sweden,

Salipro Biotech and DyNAbind enter collaboration agreement

Stockholm, Sweden / Dresden, Germany, 09 November 2020 – Salipro Biotech AB and DyNAbind GmbH are teaming up to tackle drug discovery against challenging membrane protein targets! By bringing together Salipro’s proprietary membrane stabilizing platform technology with DyNAbind’s proprietary DNA-Encoded Library (DEL) technologies, the teams aim to accelerate the development of novel drugs for these contemporary targets. Jens Frauenfeld, co-founder and CEO of Salipro Biotech AB: “We are excited to develop novel hits for challenging drug targets such as GPCR and Ion Channels with DyNAbind.

Aker Solutions ASA: Update on Contemplated Merger With Kværner ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. November 9, 2020 - Reference is made to the previous stock exchange announcements made by Aker Solutions ASA (“Aker Solutions”) regarding the contemplated merger with Kværner ASA (“Kvaerner”) as further set out in the merger plan dated July 17, 2020

Subscription period for Subsequent Offering ends today

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. Reference is made to the stock exchange notice by Solstad Offshore ASA (the "Company") on 26 October 2020 regarding the commencement of the subscription period for the subsequent offering of 1,336,973 new shares, each with a par value of NOK 1.00 (

Grant of Options subject to shareholder approval - Mandatory notification of options and shareholding

Reference is made to announcement on 1. November regarding grant of options, subject to shareholder approval, in Otello Corporation. The strike price has been determined based on the volume weighed averaged trading price the Company's shares 5 trading days after the date of grant (2. November – 6. November). The strike price is determined to be 18.99kr.   Petter Lade, CFO Phone: +47 91143878 E-mail: petterl@otellocorp.com   About Otello: Otello holds shares in several different businesses, including (i) AdColony which helps publishers monetize their content through

First hospital in unique digital pathology network in UK now live with Sectra’s solution

Linköping, Sweden – November 9, 2020 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has deployed its software for medical imaging at Leeds Teaching Hospitals. It is the first of an initial six trusts in the Northern Pathology Imaging Co-operative (NPIC) to go live, paving the way for one of the most sophisticated interconnected pathology initiatives in the world. The technology from Sectra will underpin the regional program that is digitizing, connecting and applying artificial intelligence to pathology services in the North of

Interim Report Q3 - July - September, 2020 Redsense Medical AB (publ)

FINANCIAL SUMMARY Third quarter, 1 July – 30 September 2020 The Redsense Group · Net sales amounted to KSEK 2,107 (4,645), a 55 percent decrease compared with the corresponding period in 2019. · Profit or loss before tax amounted to KSEK -3,723 (-590). The Swedish Parent Company · Net sales amounted to KSEK 1,595 (3,257). · Profit or loss before tax amounted to KSEK -3,170 (-895). 1 January – 30 September 2020 The Redsense Group · Net sales amounted to KSEK 12,213 (9,439), a 29 percent increase compared with the corresponding period in 2019. · Profit

Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia

9 November 2020 07:00 GMT Calquence approved in the EU for thetreatment of chronic lymphocytic leukaemia Calquence demonstrated superior progression-free survival and favourable tolerability in both previously untreated and relapsed or refractory patients AstraZeneca's Calquence (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was

Climate change and rainy winters pose challenges to the construction industry

YIT Corporation News November 9, 2020 at 09:00More important than individual innovation is the establishment of common, simple ground rules for the industry, as they can prevent up to 80% of all issues. Global warming is advancing faster than ever before, resulting in various alarming phenomena around the world. In the North, the rapidly melting polar glaciers have become the symbol of global warming. The climate emergency is also impacting the everyday lives of Finns on a smaller, though still significant, scale: the past few winters have been exceptionally warm, especially in southern

Flexion Mobile signs game distribution deal with Deca Games

LONDON, 9th of November, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has signed a new distribution agreement with Deca Games for Gods & Glory: War for the Throne. This is a game that Flexion has previously distributed for Wargaming Group and the publishing rights for the game have been acquired by Deca Games. According to Sensortower the game generated USD 300,000 in net revenues in Google Play in September. "It is great to have Deca Games onboard. There are lots of synergies between us and we hope to launch more games with

Cell ageing can be slowed by oxidants

At high concentrations, reactive oxygen species – known as oxidants – are harmful to cells in all organisms and have been linked to ageing. But a study from Chalmers University of Technology, Sweden, has now shown that low levels of the oxidant hydrogen peroxide can stimulate an enzyme that helps slow down the ageing of yeast cells. One benefit of antioxidants, such as vitamins C and E, is that they neutralise reactive oxygen species – known as oxidants – which may otherwise react with important molecules in the body and destroy their biological functions. Larger amounts of

Polygon AB (publ) - Interim report 1 January - 30 September 2020

Continued strong performance in uncertain timesTHIRD QUARTER 2020 · Sales grew 8.6% to EUR 187.9 million, organic growth amounted to 6.8% and acquired growth contributed 2.1%. · Adjusted EBITA amounted to EUR 13.8 million, an increase of 13% compared to last year. · Operating profit amounted to EUR 11.7 million (10.5). · Polygon has acquired Hiotlabs in Sweden, Aretech and Hydrotech in France, UTG in Luxembourg and Recotech in Italy. · For the third quarter 2020, the impact of the covid-19 outbreak has been limited for the Group. JANUARY – SEPTEMBER  2020 · Sales

Digital edition of METRO becomes exclusively available on Readly

Readly , the European category leader in digital magazines, adds METRO to its growing portfolio of newspapers and magazines. METRO, published by dmg media is the ninth national daily newspaper to be added to the Readly platform as publishers seek to broaden audience reach and gain access to data insights generated by the all-you-can-read service.METRO UK edition is available on the Readly platform from today and the Scottish edition will be available before the end of the year. Readly has an exclusive partnership with METRO where it is the only platform to host the

Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020

Stockholm, November 9, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company’s partner Eisai at the Clinical Trials on Alzheimer’s Disease conference (CTAD), November 4-7. The presentations included study design and initial screening results from the Phase 3 study AHEAD 3-45, the baseline characteristics of currently enrolled Alzheimer’s disease patients in the Phase 3 study Clarity AD, and an update on the effect of BAN2401 on amyloid brain levels and the ARIA-E frequency for patients enrolled

Statement by the Board of Directors of Internationella Engelska Skolan in view of the increased offer price in Peutinger AB's mandatory offer

Despite the fact that Peutinger’s public takeover offer has been found not to represent the full value of Internationella Engelska Skolan, the independent members of the Board of Directors unanimously recommends the shareholders to accept the public takeover offer. Background On 25 September 2020, Peutinger AB (the "Offeror"), owned by a consortium led by Paradigm Capital Value Fund SICAV, as well as Paradigm Capital Value LP, The Hans and Barbara Bergström Foundation, AB Tuna Holding, certain investors which are advised by Paradigm Capital AG (investment advisor to Paradigm Capital

KVÆRNER ASA: UPDATE ON THE CONTEMPLATED MERGER WITH AKER SOLUTIONS ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 9 November 2020 – Reference is made to the previous stock exchange announcements made by Kværner ASA (“Kvaerner”) regarding the contemplated merger with Aker Solutions ASA (“Aker Solutions”) as further set out in the merger plan dated 17 July 2020 (

Gränges appoints new management for the operations in Europe

In connection with the closing of the acquisition of Aluminium Konin, Gränges appoints a new management for the operations in Europe. Gränges’ operations in Europe consist of the acquired business Aluminium Konin in Poland, the operations in Finspång in Sweden, and the business unit Gränges Powder Metallurgy. The name of the acquired business in Poland will be changed to Gränges Konin S.A., and the name of the Swedish unit will be changed from Gränges Sweden AB to Gränges Finspång AB. Torbjörn Sternsjö, currently SVP Technology & Business Development at Gränges Group, has been

Skanska is divesting its ownership in Elizabeth River Crossings in Virginia, USA, for USD 625M, about SEK 5.4 billion

Skanska has signed a binding Sale and Purchase Agreement (“SPA”) for its 50 percent ownership stake in Elizabeth River Crossings HoldCo LLC, (“ERC”) in Hampton Roads Metropolitan Area, Virginia, USA for gross sale proceeds of USD 625M (to be adjusted by transaction costs and other items), about SEK 5.4 billion. The buyer is Abertis, and Manulife Investment Management, on behalf of John Hancock Life Insurance Company (U.S.A.). The transaction will be recorded at closing under Central stream, which is expected to be in the fourth quarter of 2020.ERC was established by Skanska and Macquarie

SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

· The Data Safety Monitoring Board (DSMB) finds no safety concerns in the 50 mg and 100 mg dose cohorts · Signs of efficacy against rheumatoid arthritis was observed. Thus, the number of patients changing from the severe to the moderate Clinical Disease Activity Index (CDAI) score was higher than placebo in both treatment groups in a dose dependent manner · The DSMB recommends that the study continues to Part 2 in which the patients are randomized to 50 mg AP1189, 100 mg AP1189 and placebo plus methotrexate (MTX) · Full Phase 2 topline data is expected by the end of Q2 2021Lund,

Fintech startup Payer launches beta test program to revolutionize customer registration in B2B e-commerce

Payer Financial Services (Payer) has developed a new registration product that revolutionizes how customer relationships are made between companies online. The product enables e-commerce merchants to verify new customers as trustworthy so they can make their purchases with ease. Today, Payer launches a beta test program with several B2B merchants.The Swedish B2B payments startup Payer is known for its modular B2B payments platform. The new product, yet to be named, was developed to meet market expectations for better buying experiences in the B2B e-commerce segment. “B2B expectations for

New Data Reveals Election’s Impact on Americans Sleep

GOTHENBURG, Sweden – November 9, 2020 – If you lost sleep on election night, you’re not alone. Sleep Cycle , the world’s most popular intelligent alarm clock app that analyzes users’ sleep, today released a new report  revealing how Americans’ sleep was impacted on election night. Using tracked sleep data and survey responses regarding election night, the report finds that of the 40% of survey participants who reported being impacted by the election, 96% were impacted negatively.2020 has been a year of

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (OMX Nasdaq: CALTX, NASDAQ: CALT) (”Calliditas”) today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).The trial met its primary objective of demonstrating a statistically significant reduction in urine protein creatinine ratio, UPCR or proteinuria, after 9 months of treatment with 16 mg of Nefecon compared to placebo, with significant continued improvement at 12 months. The trial also met the key secondary endpoint

Insplorion has completed a directed issue of MSEK 30, has resolved to carry out a fully guaranteed rights issue of a maximum of MSEK 30.3, and intends to change listing to Nasdaq First North

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH MEASURE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN WHAT FOLLOW BY SWEDISH LAW.. Insplorion AB (publ) (”Insplorion” or the ”Company”) has, following a resolution by the board of directors with the support of the authorisation from the annual general meeting, carried out a directed issue of 1,500,000 shares at a subscription price of SEK 20

There are no items matching the current filter
There are no more items matching the current filter
Back to top